Antibodies targeting CTLA-4 (Cytotoxic T-lymphocyte associated protein-4), PD-1 (Programmed cell death protein 1), or its ligand PD-L1 (Programmed death-ligand 1), are used in various cancer therapies [8]. This evidence concerns the gene PDCD1 and cancer.